Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Similar articles for PubMed (Select 23993097)

1.

A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.

Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N.

Cell. 2013 Aug 29;154(5):1074-84. doi: 10.1016/j.cell.2013.07.029.

2.

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.

Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schröder FH, de Jong FH.

Cancer Res. 2010 Feb 1;70(3):1256-64. doi: 10.1158/0008-5472.CAN-09-2092. Epub 2010 Jan 19.

3.

Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N.

Clin Cancer Res. 2012 Jul 1;18(13):3571-9. doi: 10.1158/1078-0432.CCR-12-0908.

4.

Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.

Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R.

Clin Cancer Res. 2013 Oct 15;19(20):5613-25. doi: 10.1158/1078-0432.CCR-13-1151. Epub 2013 Aug 30.

5.

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM.

Cancer Res. 2011 Feb 15;71(4):1486-96. doi: 10.1158/0008-5472.CAN-10-1343. Epub 2011 Feb 8.

6.

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer.

Wilson EM.

Asian J Androl. 2014 Jan-Feb;16(1):99-100. doi: 10.4103/1008-682X.122200. No abstract available.

7.

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13728-33. doi: 10.1073/pnas.1107898108. Epub 2011 Jul 27.

8.

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.

Ishizaki F, Nishiyama T, Kawasaki T, Miyashiro Y, Hara N, Takizawa I, Naito M, Takahashi K.

Sci Rep. 2013;3:1528. doi: 10.1038/srep01528.

9.

Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.

Hamid AR, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FC, Sedelaar JP, Schalken JA.

Mol Med. 2013 Jan 22;18:1449-55. doi: 10.2119/molmed.2012.00296.

10.

The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.

Sharifi N.

J Investig Med. 2012 Feb;60(2):504-7. doi: 10.231/JIM.0b013e31823874a4. Review.

11.

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI.

Cancer Res. 2012 Dec 1;72(23):6142-52. doi: 10.1158/0008-5472.CAN-12-1335. Epub 2012 Sep 12.

12.

3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.

Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N.

Endocrinology. 2010 Aug;151(8):3514-20. doi: 10.1210/en.2010-0138. Epub 2010 Jun 9.

PMID:
20534728
13.

Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.

Campbell TJ, Tindall DJ, Figg WD.

Cancer Biol Ther. 2012 Mar;13(5):237-8. doi: 10.4161/cbt.19608. Epub 2012 Mar 1.

14.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP.

Cancer Res. 2006 Mar 1;66(5):2815-25.

15.

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.

Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E.

BMC Cancer. 2010 May 28;10:244. doi: 10.1186/1471-2407-10-244.

16.

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.

Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.

17.

Prostate cancer: Steroid enzyme mutated in CRPC.

Payton S.

Nat Rev Urol. 2013 Oct;10(10):555. doi: 10.1038/nrurol.2013.216. Epub 2013 Sep 17. No abstract available.

PMID:
24042568
18.

Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.

Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, Stolz A.

Prostate. 2003 Mar 1;54(4):275-89. Erratum in: Prostate. 2006 Mar 1;66(4):445.

PMID:
12539226
19.

Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.

Titus MA, Zeithaml B, Kantor B, Li X, Haack K, Moore DT, Wilson EM, Mohler JL, Kafri T.

PLoS One. 2012;7(1):e30192. doi: 10.1371/journal.pone.0030192. Epub 2012 Jan 17.

20.

Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.

Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB.

PLoS One. 2012;7(1):e30062. doi: 10.1371/journal.pone.0030062. Epub 2012 Jan 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk